Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

New EACS 2025 data show once-weekly islatravir and lenacapavir maintain HIV viral suppression for 96 weeks with no resistance ...

Merck (NYSE:MRK) reported positive results from late-stage studies on a new oral treatment which combines two drugs, ...

HIV remains a major global health issue, affecting nearly 40 million people worldwide. Current treatments, known as ...

Over the past three decades, there have been amazing advances in treating and preventing HIV. Subscribe to our newsletter for the latest sci-tech news updates. It's now a manageable infection. A ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data ...

Lenacapavir has the potential to end the HIV epidemic, researchers say. The Trump administration says backing this kind of ...

DUBLIN--(BUSINESS WIRE)--The "HIV Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for HIV Drugs was valued at US$32.8 Billion in ...

Sofosbuvir, a hepatitis C treatment drug, can adversely interact with tenofovir disoproxil, a HIV treatment drug, according to research led by Bingfang Yan, PhD, professor of biomedical and ...

A growing trend of injecting the blood of other drug users to get a quick high, a practice called “bluetoothing”, has been ...